T Jesse Kwoh
Overview
Explore the profile of T Jesse Kwoh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
864
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Conceicao I, Berk J, Weiler M, Kowacs P, Dasgupta N, Khella S, et al.
J Neurol
. 2025 Feb;
272(2):182.
PMID: 39899052
No abstract available.
2.
Wixner J, Berk J, Adams D, Polydefkis M, Conceicao I, Attarian S, et al.
Amyloid
. 2024 Nov;
32(1):29-38.
PMID: 39552152
Background: The NEURO-TTRansform trial showed that after 66 weeks of treatment, eplontersen significantly reduced neuropathic impairment and improved quality of life (QoL) in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy...
3.
Conceicao I, Berk J, Weiler M, Kowacs P, Dasgupta N, Khella S, et al.
J Neurol
. 2024 Aug;
271(10):6655-6666.
PMID: 39138650
Background: The phase 3 NEURO-TTRansform trial showed eplontersen treatment for 65 weeks reduced transthyretin (TTR), halted progression of neuropathy impairment, and improved quality of life (QoL) in adult patients with...
4.
Partridge W, Burel S, Ferng A, Xia S, Kwoh T, Henry S, et al.
Clin Transl Sci
. 2023 Jan;
16(4):575-580.
PMID: 36631935
This analysis sought to assess the clinical predictivity of an in vitro assay which utilized the human B-lymphoma BJAB cell line, for identification of antisense oligonucleotides (ASOs) with the potential...
5.
Baker B, Xia S, Partridge W, Kwoh T, Tsimikas S, Bhanot S, et al.
Nucleic Acid Ther
. 2022 Dec;
33(1):72-80.
PMID: 36454263
Receptor-mediated delivery of an antisense oligonucleotide (ASO) using the ligand-conjugated antisense technology is establishing a new benchmark for antisense therapeutics. The triantennary -acetylgalactosamine (GalNAc) cluster is the first conjugated ligand...
6.
Burel S, Machemer T, Baker B, Kwoh T, Paz S, Younis H, et al.
Nucleic Acid Ther
. 2022 Aug;
32(6):457-472.
PMID: 35976085
A human peripheral blood mononuclear cell (PBMC)-based assay was developed to identify antisense oligonucleotide (ASO) with the potential to activate a cellular innate immune response outside of an acceptable level....
7.
Han K, Theodore D, McMullen G, Swayze E, McCaleb M, Billioud G, et al.
Clin Pharmacol Drug Dev
. 2022 Aug;
11(10):1191-1202.
PMID: 35971951
Dose-dependent reductions in hepatitis B virus (HBV) RNA, DNA, and viral proteins following bepirovirsen administration were observed in HepG2.2.15 cells. In HBV-transgenic mice treated at 50 mg/kg/wk, hepatic HBV RNA...
8.
Yuen M, Heo J, Jang J, Yoon J, Kweon Y, Park S, et al.
Nat Med
. 2021 Oct;
27(10):1725-1734.
PMID: 34642494
Chronic infection with hepatitis B virus (HBV) leads to an increased risk of death from cirrhosis and hepatocellular carcinoma. Functional cure rates are low with current treatment options (nucleos(t)ide analogs...
9.
Partridge W, Xia S, Kwoh T, Bhanot S, Geary R, Baker B
Nucleic Acid Ther
. 2021 Jul;
31(6):417-426.
PMID: 34242101
The development process of antisense oligonucleotides (ASOs) as therapeutic agents in humans has advanced through the implementation of chemical compound modifications as well as increasingly sophisticated toxicological preclinical screening techniques....
10.
Narayanan P, Curtis B, Shen L, Schneider E, Tami J, Paz S, et al.
Nucleic Acid Ther
. 2020 Feb;
30(2):94-103.
PMID: 32043907
Inotersen, a 2'-O-methoxyethyl (2'-MOE) phosphorothioate antisense oligonucleotide, reduced disease progression and improved quality of life in patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) in the NEURO-TTR and NEURO-TTR open-label...